Skip to Content

We invite you to try out our new beta eCFR site at https://ecfr.federalregister.gov. We’ve made big changes to make the eCFR easier to use. Be sure to leave feedback using the 'Help' button on the bottom right of each page!

Notice

Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

ACTION:

Notice of application.

DATES:

Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 17, 2020.

ADDRESSES:

Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.33(a), this is notice that on May 6, 2020, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616-3466, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances:

Controlled substanceDrug codeSchedule
Gamma Hydroxybutyric Acid2010I
Amphetamine1100II
Lisdexamfetamine1205II
Methylphenidate1724II
ANPP (4-Anilino-N-phenethyl-4-piperidine)8333II
Phenylacetone8501II
Codeine9050II
Oxycodone9143II
Hydromorphone9150II
Hydrocodone9193II
Morphine9300II
Oripavine9330II
Thebaine9333II
Opium extracts9610II
Opium fluid extract9620II
Opium tincture9630II
Opium, powdered9639II
Oxymorphone9652II
Noroxymorphone9668II
Fentanyl9801II

The company plans to manufacture the above-listed controlled substances in bulk for conversion to other controlled substances and sales to its customers for dosage form development, clinical trials and use in stability qualification studies. No other activities for these drug codes are authorized for this registration.

Start Signature

William T. McDermott,

Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2020-13009 Filed 6-16-20; 8:45 am]

BILLING CODE 4410-09-P